Abilify Maintena (aripiprazole extended release) / Otsuka, BMS, Lundbeck - LARVOL DELTA

Interaction Between Oxcarbazepine and Long-Acting Aripiprazole Leading to Relapse of Bipolar Disorder. (PubMed, Prim Care Companion CNS Disord) - No abstract available

Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

Factors Affecting Continuation of Aripiprazole Long-acting Injection in the Real World. (PubMed, Clin Psychopharmacol Neurosci) - "This study supports the clinical effectiveness of aripiprazole LAI, demonstrated by a reduced one-year discontinuation rate compared to that observed in a paliperidone LAI study with a similar design. Large-scale, long-term prospective studies are essential to definitively ascertain the factors associated with LAI discontinuation."

Journal • Real-world evidence • CNS Disorders

Long-Standing Akathisia Associated With Long-Acting Injectable Aripiprazole: A Case Report. (PubMed, J Clin Psychopharmacol) - No abstract available

Journal

Management of a Complex Case of Primary Enuresis in an Adult With Attention-Deficit Hyperactivity Disorder: A Case Report. (PubMed, Cureus) - "She was treated with 10 mg oral escitalopram once daily and a monthly intramuscular injection of 400 mg aripiprazole extended-release, with no reported improvement in her symptoms. Along with her current medications, she was started on 18 mg methylphenidate once daily and lamotrigine, started by 25 mg once daily, titrated to 50 mg. This adjustment led to significant improvement in her symptoms and the resolution of her enuresis. This case report demonstrates the resolution of ADHD symptoms along with the primary enuresis in an adult female patient who was treated with methylphenidate."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • Borderline Personality Disorder • CNS Disorders • Mood Disorders • Personality Disorder • Psychiatry • Urinary Incontinence

C-Cog in Early Course Schizophrenia Study (clinicaltrials.gov) - P4 | N=60 | Terminated | Sponsor: University of Miami | Trial completion date: Jul 2025 ➔ Mar 2025 | Recruiting ➔ Terminated; Recruitment issues

Trial completion date • Trial termination • CNS Disorders • Psychiatry • Schizophrenia

Liver dysfunction and long-acting aripiprazole: The importance of tolerability assessment. (PubMed, Int J Clin Pharmacol Ther) - No abstract available

Journal • Hepatology • Liver Failure

Survey on the Initiation of Aripiprazole Once-Monthly via a Two-Injection Start in Adult Patients with Schizophrenia: Experience of European Healthcare Professionals. (PubMed, Adv Ther) - "European HCPs reported that AOM 400-TIS was easy to administer, well tolerated, and improved treatment outcomes. Barriers to its use included patient reluctance and perceived safety concerns."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Acute dystonia following the two-injection start of aripiprazole once-monthly. (PubMed, BMJ Case Rep) - "The ADR occurred two times within 3 weeks of the two-injection start and was effectively treated with benztropine each time. The two-injection start of AOM has been approved by regulatory bodies on the basis of population pharmacokinetic modelling. Our case may, therefore, identify a new safety concern with this alternative initiation option that was not captured in the modelling."

Journal • CNS Disorders • Dystonia • Infectious Disease • Movement Disorders • Psychiatry • Schizophrenia

Efficacy and Safety of Adjunctive Aripiprazole LAI or Paliperidone LAI for the Management of Patients Suffering from Bipolar I Disorder with Comorbid Obsessive-Compulsive Disorder. (PubMed, J Clin Med) - "The use of long-acting injectable (LAI) antipsychotics such as monthly aripiprazole (ARI-LAI) and monthly paliperidone (PP-LAI) has been proposed as a promising alternative for BD treatment, while their efficacy and safety in BD-OCD remain understudied... 27 BD-OCD patients were treated with ARI-LAI or PP-LAI, alongside mood stabilizers (MS) (lithium or sodium valproate), over a 24 week period... This study is the first that investigated the efficacy and safety of adjunctive PP-LAI and ARI-LAI in this population highlighting their potential as effective and well-tolerated options for managing BD-OCD. Further studies are needed to confirm these results and refine treatment strategies for this complex population."

Journal • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry

Optimising Aripiprazole Long-Acting Injectable: A Comparative Study of One- and Two-Injection Start Regimens in Schizophrenia with and Without Substance Use Disorders and Relationship to Early Serum Levels. (PubMed, Int J Mol Sci) - "Here we showed no disadvantages for TIS vs. OIS and possibly increased safety. Shifting the initiation of aripiprazole LAIs to the TIS modality may be safe and pharmacokinetically advantageous."

Clinical • Journal • CNS Disorders • Psychiatry • Schizophrenia

Real-World Effectiveness of Long-Acting Injectable and Oral Antipsychotic Agents in US Medicare Patients with Schizophrenia. (PubMed, Adv Ther) - "Efforts are needed to enhance identification of appropriate candidates for LAIs and increase their uptake, especially longer dosing interval LAIs, in the Medicare population."

Journal • Medicare • Real-world evidence • Reimbursement • US reimbursement • CNS Disorders • Psychiatry • Schizophrenia

A review of clinical applications of pharmacokinetic simulations for a 2-month long-acting injectable formulation of aripiprazole. (PubMed, Curr Med Res Opin) - "Aripiprazole 2-month ready-to-use (Ari 2MRTU) is a long-acting injectable antipsychotic that was approved for use in Europe in March 2024, for the maintenance treatment of schizophrenia in adult patients stabilized with aripiprazole; it is administered via gluteal intramuscular injection once every two months...Various simulations conducted across 8 weeks (representing the first dosing interval), or 32 weeks (representing maintenance dosing) demonstrated an aripiprazole exposure profile for Ari 2MRTU that was similar to aripiprazole once-monthly (AOM), but with an extended dosing interval...The availability of Ari 2MRTU extends the range of options for the maintenance treatment of schizophrenia in Europe. Ari 2MRTU may provide adherence benefits due to its extended dosing interval and the option to initiate treatment using a two-injection start regimen, which does not require 14 days of overlapping oral supplementation."

Journal • PK/PD data • Review • CNS Disorders • Psychiatry • Schizophrenia

Partial Dopamine D2/3 Agonists and Dual Disorders: A Retrospective-Cohort Study in a Real-World Clinical Setting on Patients with Schizophrenia Spectrum Disorders and Cannabis Use Disorder. (PubMed, Curr Neuropharmacol) - "Partial D2/3 agonists may treat comorbid schizophrenia/schizoaffective disorder and cannabis use disorder, improving the symptoms of both disorders and substance craving."

Journal • Real-world evidence • Retrospective data • CNS Disorders • Psychiatry • Schizophrenia • Substance Abuse

Long-acting Injectable Aripiprazole (Abilify Maintena) Induced Rabbit Syndrome: A Case Report and Review of the Literature. (PubMed, Clin Psychopharmacol Neurosci) - "This case emphasizes the significance of RS in LAIs-treated patients and emphasizes the need for further research into its mechanisms and optimal management strategies. Additionally, an updated review of RS associated with newer generation antipsychotics is provided to enhance understanding and clinical management."

Journal • Preclinical • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • Schizophrenia

Treatment With Long-Acting Injectable Aripiprazole During Pregnancy in Bipolar Disorder: A Scoping Review. (PubMed, Am J Ther) - "The scoping review emphasizes the need for further research to confirm its safety and efficacy. The limited data underscore the importance of individualized treatment plans and informed decision-making, considering the unique risks and benefits of LAI antipsychotic use during pregnancy. Further studies are imperative to provide more definitive guidance for managing bipolar disorder with LAI antipsychotics in pregnant patients."

Journal • Review • Bipolar Disorder • CNS Disorders • Mental Retardation • Mood Disorders • Psychiatry

The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia (clinicaltrials.gov) - P4 | N=15 | Completed | Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Nov 2024 | Trial primary completion date: Sep 2022 ➔ Aug 2024

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Cost-effectiveness of ten commonly used antipsychotics in first-episode schizophrenia in the UK: economic evaluation based on a de novo discrete event simulation model. (PubMed, Br J Psychiatry) - "Our findings suggest amisulpride (or risperidone-LAI where oral treatment is inappropriate) as the best overall first-line option based on QALYs and cost-effectiveness. Our ranking may be used to guide decision-making between antipsychotics. Our model is open source and could be applied to the other settings."

HEOR • Journal • Cardiovascular • CNS Disorders • Psychiatry • Schizophrenia

Long-term effectiveness of aripiprazole once monthly on functioning and quality of life in schizophrenia: results of year 2 of the ReLiAM study. (PubMed, BMC Psychiatry) - P=N/A | "These findings suggest that the favorable effectiveness, including tolerability observed during the first year following AOM initiation, are maintained and may even continue to improve during the second year of treatment."

HEOR • Journal • Observational data • CNS Disorders • Insomnia • Psychiatry • Schizophrenia • Sleep Disorder

Plain Language Summary of Publication: A comparison of once-monthly and once-every-2-months injectable formulations of aripiprazole in people with schizophrenia. (PubMed, Ther Adv Psychopharmacol) - "The purpose of this summary is to explain key findings from a study that included people with schizophrenia, as described in two separate articles (see the 'Further Information' section for more details). The study compared a new formulation of aripiprazole, given as an injection once every 2 months, with a once‑monthly injection of aripiprazole."

Journal • Review • CNS Disorders • Psychiatry • Schizophrenia

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication (clinicaltrials.gov) - P2 | N=233 | Completed | Sponsor: Astellas Pharma Global Development, Inc. | Phase classification: P2a ➔ P2

Phase classification • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Aripiprazole once-monthly for the treatment of adult patients with earlier-stage bipolar I disorder: a post hoc analysis of data from a double-blind, placebo-controlled, 52-week randomized withdrawal trial. (PubMed, Int J Bipolar Disord) - P3 | "In this post hoc analysis, AOM 400 prolonged time to recurrence of any mood episode versus placebo in earlier-stage BP-I. These findings support early initiation of maintenance treatment with AOM 400."

Journal • Retrospective data • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Oral and Long-acting Injectable Aripiprazole in Severe Mental Illness and Substance Use Disorder Comorbidity: An Updated Systematic Review. (PubMed, Curr Neuropharmacol) - "The present findings suggest aripiprazole may be associated with reducing substance craving and improving depression, psychosis, and schizoaffective disorders in dually diagnosed patients."

Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia

Exploring the efficacy and tolerability of two-injection start regimen of long-acting aripiprazole: A descriptive case series analysis. (PubMed, Neuropsychopharmacol Rep) - "We observed that the double injection start regimen was effective in treating manic symptoms with no specific severe adverse events. We conclude from a small sample of manic patients that a double injection start regimen has good efficacy and tolerability."

Journal • Bipolar Disorder • CNS Disorders • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia

Clinical Reasoning in the Use of Long-acting Aripiprazole in Psychosis in Bilateral Nephrectomy on Hemodialysis. (PubMed, Clin Psychopharmacol Neurosci) - "Based on its pharmacological and pharmacokinetic properties oral aripiprazole 20 mg was commenced and after establishing tolerability and response, the patient was switched to long-acting aripiprazole 400 mg monthly achieving full remission of psychotic symptoms after 6 months with maintained improvement after 12 months. Based on its properties, aripiprazole may be a reasonable option in the treatment of psychosis in patients on hemodialysis with nephrectomy and can be considered even as a long-acting injection in these patients."

Journal • Chronic Kidney Disease • CNS Disorders • Mental Retardation • Nephrology • Psychiatry • Renal Disease

Comparative Effectiveness of Antipsychotics in Patients With Schizophrenia Spectrum Disorder. (PubMed, JAMA Netw Open) - "Compared with oral olanzapine, paliperidone 3-month long-acting injectable (LAI) was associated with the lowest adjusted hazard ratio (AHR) in the prevention of relapses (AHR, 0.66; 95% CI, 0.51-0.86), followed by aripiprazole LAI (AHR, 0.77 [95% CI, 0.70-0.84]), olanzapine LAI (AHR, 0.79 [95% CI, 0.73-0.86]), and clozapine (AHR, 0.82 [95% CI, 0.79-0.86]). Quetiapine was associated with the highest risk of relapse (AHR, 1.44 [95% CI, 1.38-1.51])...This comparative effectiveness research study demonstrated large differences in the risk of relapse and treatment failure among specific antipsychotic treatments. The findings contradict the widely held conception that all antipsychotics are equally effective in relapse prevention."

Clinical • HEOR • Journal • CNS Disorders • Psychiatry • Schizophrenia